Scarica l'app Stockscreener
329.20
0.53%
-1.57
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PODD Giù?
Forum
Previsione
Insulet Corporation Borsa (PODD) Ultime notizie
No. 1 Medical Device Maker Insulet In 11 Stocks New To IBD Lists - Investor's Business Daily
Insulet stock hits 52-week high at $329.55 - Investing.com
Cisco, Rocket Companies, Insulet And More On CNBC's 'Final Trades' - Benzinga
Insulet Corp to Present at Upcoming Investor Conferences Amidst Diabetes Management Focus - AInvest
Why This IBD Stock Of The Day Just Broke Out — Again - Investor's Business Daily
Final Trades: Rocket Companies, Cisco Systems, Insulet Corp and the IGV - MSN
Insulet to Participate in Upcoming Investor Conferences - Business Wire
Insulet Corporation : There is still some upside potential - MarketScreener
Is Insulet Corporation subject to activist investor interest2025 Market WrapUp & AI Powered Trade Plan Recommendations - thegnnews.com
Insulet’s (PODD) Aggressive Revenue Guidance and Buyback Might Change the Case for Investing - simplywall.st
Published on: 2025-08-16 12:18:14 - sundaytimes.kr
Insulet Shares Soar on Volume Surge as Stock Ranks 495th in Market Activity for the Day - AInvest
Quant Strategy Flags Insulet Corporation for EntryJuly 2025 Catalysts & High Accuracy Trade Signal Alerts - newsyoung.net
Short Covering May Lift Insulet Corporation in Near TermQuarterly Profit Review & Weekly High Return Opportunities - sundaytimes.kr
Stock Market Today: Indexes Hold Strong, But Small Caps Lag; Netflix, Amazon, Insulet In Focus - Investor's Business Daily
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings - simplywall.st
Insulet's (NASDAQ:PODD) Conservative Accounting Might Explain Soft Earnings - Yahoo Finance
Investors Can Find Comfort In Insulet's (NASDAQ:PODD) Earnings Quality - 富途牛牛
The Top 5 Analyst Questions From Insulet’s Q2 Earnings Call - Yahoo Finance
Insulet’s Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold (PODD) - Seeking Alpha
Elliott Wave Theory Predicts Pullback in Insulet CorporationEarnings Miss & Intraday High Probability Setup Alerts - beatles.ru
Sapiens International Q2 Earnings Decline, Revenue Rises Amid Acquisition Deal - AInvest
PODD Q2 Deep Dive: Omnipod 5 Adoption and International Expansion Drive Results - Yahoo Finance
Insulet Rises to 470th in Trading Volume as Q2 Revenue Surges 32.9 and Margins Expand - AInvest
Insulet Q2 Earnings and Revenue Exceed Estimates, Stock Rises, Margins Improve - AInvest
Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise - TradingView
Insulet Corporation Reports Strong Q2 2025 Growth - MSN
Why Insulet (PODD) is a Top Growth Stock for the Long-Term - sharewise.com
Insulet Corp: Strong Financial Position and Competitive Strengths - AInvest
Why Insulet (PODD) Is Up 7.8% After Raising Full-Year Revenue Guidance on Omnipod Momentum - simplywall.st
Is It Too Late to Sell Insulet CorporationLow Drawdown Real Time Trading Tips Shared - beatles.ru
Price Consolidation Hints at Upcoming Move in Insulet CorporationFast Exit and Entry Strategy Guide Offered - beatles.ru
Insulin pump makers Tandem and Insulet post contrasting Q2 results - MSN
Insulet's Insider Activity and Executive Compensation Transparency: A Governance and Investor Sentiment Analysis - AInvest
Insulet’s Earnings Call Highlights Robust Growth and Optimism - The Globe and Mail
Research Alert: CFRA Maintains Hold Opinion On Shares Of Insulet Corporation - 富途牛牛
RBC Capital Raises PT for Insulet to $350, Maintains Outperform Rating - AInvest
Insulet Corporation shares rise 2.61% intraday after multiple brokerages raised price targets. - AInvest
Insulet (PODD) Is Up 5.3% After Raising Full-Year Revenue Guidance on Strong Q2 Sales – Has The Bull Case Changed? - simplywall.st
Baird Adjusts Price Target on Insulet to $360 From $350, Maintains Outperform Rating - MarketScreener
Insulet stock price target raised to $350 from $330 at RBC Capital - Investing.com Canada
Bernstein raises Insulet stock price target to $400 on type 2 diabetes growth - Investing.com Nigeria
RBC Raises Price Target on Insulet to $350 From $330, Keeps Outperform Rating - MarketScreener
Insulet price target raised to $350 from $330 at RBC Capital - TipRanks
Insulet Corporation (PODD) PT Raised to $350 at RBC Capital - StreetInsider
Insulet Corporation (NASDAQ:PODD) Q2 2025 Earnings Call Transcript - Insider Monkey
Insulet Corporation (PODD) PT Raised to $400 at Bernstein SocGen Group - StreetInsider
Insulet price target raised to $353 from $331 at Canaccord - TipRanks
Morgan Stanley Raises Price Target on Insulet to $370 From $355, Keeps Overweight Rating - MarketScreener
Goldman Sachs Adjusts Price Target on Insulet to $399 From $380, Maintains Buy Rating - MarketScreener
Canaccord Genuity Adjusts Price Target on Insulet to $353 From $331, Maintains Buy Rating - MarketScreener
Bernstein Adjusts Price Target on Insulet to $400 From $375, Maintains Outperform Rating - MarketScreener
Tandem, Insulet monitoring CMS payment proposal for diabetes tech - Yahoo Finance
Insulet: Q2 Earnings Snapshot - Connecticut Post
Insulet raises full-year 2025 revenue growth guidance to 24%-27% as Omnipod 5 drives global adoption - MSN
Insulet Corp (PODD) Q2 2025 Earnings Call Highlights: Record Revenue and Raised Guidance Amid ... By GuruFocus - Investing.com Canada
1.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):